Evaluation of BioStar® FLU OIA® assay for rapid detection of influenza A and B viruses in respiratory specimens

Journal of Clinical Virology

Volumn 17, Issue 2, 2000, Pages 119-126

  Hindiyeh, M ^a   Goulding, C ^b   Morgan, H ^b   Kenyon, B ^b   Langer, J ^b   Fox, L ^b   Dean, G ^b   Woolstenhulme, D ^b   Turnbow, A ^b   Billetdeaux, E ^b   Shakib, S ^b   Gordon, C ^b   Powers, A ^b   Vardeny, G ^b   Johnson, M ^b   Skodack Jones, L ^b   Carroll, K ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP LABORATORIES   (United States)

Author keywords

BioStar FLU OIA assay; Enzyme immunoassay; Influenza virus rapid detection

Indexed keywords

ANTIVIRUS AGENT; SIALIDASE; VIRUS ANTIGEN;

ARTICLE; CONTROLLED STUDY; CROSS REACTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; ENZYME IMMUNOASSAY; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; NONHUMAN; PRIORITY JOURNAL; TRANSPORT MEDIUM; VALIDATION PROCESS; VIRUS CULTURE; VIRUS DETECTION; ANIMAL; CELL LINE; COMPARATIVE STUDY; EVALUATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOASSAY; IMMUNOLOGY; INFLUENZA; ISOLATION AND PURIFICATION; LUNG LAVAGE; METHODOLOGY; NOSE; NOSE MUCUS; PHARYNX; SENSITIVITY AND SPECIFICITY; SPUTUM; VIROLOGY;

ANIMALS; ANTIGENS, VIRAL; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOASSAY; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; NASAL LAVAGE FLUID; NOSE; PHARYNX; SENSITIVITY AND SPECIFICITY; SPUTUM;

EID: 0033624497     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(00)00081-0     Document Type: Article

References (15)

1. Calfee D., Hayden F.G. New approaches to influenza chemotherapy neuraminidase inhibitors. Drugs. 56:1998;537-553.
2. Update: influenza activity - United States, 1998-99 season. MMWR. 48:1999;25-27.
3. Covalciuc K.A., Webb K.H., Carlson C.A. Comparison of four clinical specimens types for detection of influenza A and B viruses by optical immunoassay (FLU OIA test) and cell culture methods. J. Clin. Microbiol. 37:1999;3971-3974.
4. Douglas R. Jr Drug therapy. Prophylaxis and treatment of influenza. New Engl. J. Med. 322:1990;443.
5. Engler H.D., Selepak S.T. Effect of centrifuging shell vials at 3500×g on detection of viruses in clinical specimens. J. Clin. Microbiol. 32:1994;1580-1582.
6. Gander R., Reddy S.T., Patel S.K. Clinical evaluation of the BioStar AB FLU OIA test for direct detection of influenza types A and B in respiratory secretions. Abstracts of the 38th Annual ICAAC. 1998;H59.
7. Glezen W. Emerging infections: pandemic influenza. Epidemiol. Rev. 18:1996;64-72.
8. Hayden F.G., Treanor J.J., Betts R.F., Lobo M., Esinhart J.D., Hussey E.K. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. J. Am. Med. Assoc. 275:1996;295-299.
9. Hayden F.G., Atmar R.L., Schilling M., Jonson C., Poretz D., Paar D., Huson L., Ward P., Mills R.G. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. New Engl. J. Med. 341:1999;1336-1343.
10. Lui K.J., Kendal A.P. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am. J. Public Health. 77:1987;712-716.
11. Mendel D., Tai C.Y., Escarpe P.A., Li W., Sidwell R.W., Huffman J.H., Sweet C., Jakeman K.J., Merson J., Lacy S.A., Lew W., William M.A., Zhang L., Chen M.S., Bischofberger N., Kim C.U. Oral administration of a prodrug of the influenza virus neuroaminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents Chemother. 42:1998;640-646.
12. Piedra P.A. Influenza virus pneumonia: pathogenesis, treatment and prevention. Sem. Resp. Infect. 10:1995;216-223.
13. Rott R., Klenk H.D., Nagai Y., Tashiro M. Influenza viruses, cell enzymes, pathogenicity. Am. J. Respir. Crit. Care Med. 152:1995;S16.
14. Wintermeyer S., Nahata M.D. Rimantadine: a clinical perspective. Ann. Pharmacol. 29:1995;299.
15. Woo P., Chiu S.S., Seto W.H., Peiris M. Cost-effectiveness of rapid diagnosis of viral respiratory tract infections in pediatric patients. J. Clin. Microbiol. 35:1997;1579-1581.